Lamifiban (TFA)

Lamifiban TFA is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes[1].

Product Specifications

CAS Number

[144412-50-0]

UNSPSC

12352005

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/lamifiban-tfa.html

Smiles

OC(C(F)(F)F)=O.O=C(N1CCC(CC1)OCC(O)=O)[C@@H](NC(C2=CC=C(C=C2)C(N)=N)=O)CC3=CC=C(C=C3)O

Molecular Formula

C26H29F3N4O8

Molecular Weight

582.53

References & Citations

[1]Moliterno DJ, et al. Randomized, Placebo-Controlled Study of Lamifiban with Thrombolytic Therapy for the Treatment of Acute Myocardial Infarction: Rationale and Design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Study. J Thromb Thrombolysis. 1995;2 (3) :165-169.